There is decreased risk for CV events and mortality in patients with cardiac autonomic neuropathy that receive intensive glycemic treatment.

The prevalence of diabetes is increasing worldwide; however, its impact on routine daily activities is often underappreciated ...

While symptoms for some can be mild, others may report severe pain and loss of function. ︎ Diabetic peripheral neuropathy, which affects about 30% of diabetics, can cause numbness, tingling, or ...

Key Diabetic Peripheral Neuropathy Therapies: QUTENZA (capsaicin), TARLIGE (mirogabalin besylate), Engensis (VM202), Suzetrigine (VX-548), VM202, LX9211, GRC 17536, Ricolinostat, CBD, and others ...

Grünenthal acquired the global rights to Qutenza in 2018 as part of its growth strategy. Since 2017, the company has invested more than €2 billion in successful M&A transactions and continues ...

About Qutenza In Europe, Qutenzais indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain.

24.02.2025 – 15:43 Grünenthal Group Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal ...

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal PR Newswire TORONTO and AACHEN, Germany, Feb. 24, 2025 ...

Grünenthal acquired the global rights to Qutenza ® in 2018 as part of its growth strategy. Since 2017, the company has invested more than €2 billion in successful M&A transactions and ...